Pamrevlumab for Idiopathic Pulmonary Fibrosis

This randomized clinical trial compares the efficacy and safety of pamrevlumab vs placebo for patients with idiopathic pulmonary fibrosis.

Related Keywords

United States ,California ,San Diego ,Helsinki ,Eteläuomen Läi ,Finland ,University Of California San Diego ,South Korea ,China ,Korea ,American ,Roche Genentech ,Eisai Pharma ,Shionogi Pharma ,Ganesh Raghu ,Astellas Pharma ,Taiho Pharma ,Key Research ,International Conference On Harmonisation ,National Research Foundation Of Korea ,Bristol Myers Squibb ,Technology Of China ,National Institutes Of Health ,American Thoracic Society ,University Of Washington ,Korean National Institute Of Health ,Institute Inc ,Boehringer Ingelheim ,Drug Administration ,Group Information ,Novartis ,National Nature Foundation Of China ,Technology Institute ,Development Plan Of The Ministry Science ,Toray Industries ,African American ,International Conference ,Good Clinical Practice ,Respiratory Questionnaire ,California San Diego ,Breath Questionnaire ,Leicester Cough Questionnaire ,Efficacy Outcome ,Exploratory Outcomes ,Interest Disclosures ,United Therapeutics ,National Institutes ,Pliant Therapeutics ,National Research Foundation ,Korean National Institute ,Korean Environment Industry ,Development Plan ,National Nature Foundation ,Drs Zhang ,